Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $134.30.

A number of research analysts have recently issued reports on the company. Wedbush set a $165.00 price target on Oruka Therapeutics in a report on Monday, April 27th. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 23rd. Finally, Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $88.07 on Friday. Oruka Therapeutics has a fifty-two week low of $12.84 and a fifty-two week high of $97.78. The company has a market cap of $5.31 billion, a price-to-earnings ratio of -45.40 and a beta of -0.35. The business’s 50 day moving average price is $77.23 and its 200-day moving average price is $57.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.04. Sell-side analysts predict that Oruka Therapeutics will post -2.06 earnings per share for the current year.

Insider Activity

In other Oruka Therapeutics news, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction on Friday, June 12th. The shares were sold at an average price of $70.11, for a total value of $882,194.13. Following the transaction, the director directly owned 38,743 shares of the company’s stock, valued at approximately $2,716,271.73. The trade was a 24.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $84.63, for a total value of $846,215.37. Following the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,295,854.56. The trade was a 39.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 188,406 shares of company stock valued at $12,019,683 in the last ninety days. 23.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the last quarter. Kennedy Capital Management LLC grew its stake in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after acquiring an additional 420 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after acquiring an additional 626 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after acquiring an additional 788 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after acquiring an additional 904 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.